Akorn, GeneraMedix Sign Manufacturing Pact

Akorn, Inc. has signed a commercial manufacturing supply agreement with GeneraMedix, Inc. to manufacture injectable products in finished dosage form for GeneraMedix. Under the agreement, GeneraMedix will market these products in the GeneraMedix label. The agreement includes products currently available from Akorn, as well as select injectable products from the Akorn internal product development pipeline.

Arthur S. Przybyl, president and chief executive officer of Akorn stated, “We are excited to enter into this strategic product supply partnership with GeneraMedix. This partnership will allow us to expand our existing market share and increase our contract sales revenues. We believe that GeneraMedix and their executive management team have the experience and infrastructure to successfully market these generic products to the hospital and specialty pharmaceutical markets. We look forward to a long-standing and successful relationship.”

Ronald F. Quadrel, president and chief executive officer of GeneraMedix stated, “We are very pleased to enter into this strategic relationship with Akorn as we continue to build our injectable product portfolio. The addition of these products reinforces our long term commitment to provide a broad range of generic injectable products to hospitals, surgery centers and clinics.”